Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock, par value $0.001 per share · CUSIP: 05338F306

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Balyasny Asset Management L.P.

    Shares: 439,312 · Class: 2.42%

  • BAM GP LLC

    Shares: 439,312 · Class: 2.42%

  • Balyasny Asset Management Holdings LP

    Shares: 439,312 · Class: 2.42%

  • Dames GP LLC

    Shares: 439,312 · Class: 2.42%

  • Dmitry Balyasny

    Shares: 439,312 · Class: 2.42%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-052938
Form type
SCHEDULE 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub